For Healthcare Professionals

Addition of Daratumumab to Combination of Bortezomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma


About the study

The purpose of this study is to assess the effects of administration of daratumumab when combined with VELCADE (bortezomib) and dexamethasone compared with bortezomib and dexamethasone alone, for participants with relapsed or refractory multiple myeloma.

Who can take part

You may be eligible to participate in the study if you meet the following criteria:


  1. Must have had documented multiple myeloma
  2. Must have received at least 1 prior line of therapy for multiple myeloma
  3. Must have had documented evidence of progressive disease as defined based on Investigator's determination of response of International Myeloma Working Group (IMWG) criteria on or after their last regimen
  4. Must have an Eastern Cooperative Oncology Group Performance Status score of 0, 1, or 2
  5. Must have achieved a response (partial response [PR] or better based on investigator's determination of response by the IMWG criteria) to at least 1 prior regimen in the past


  1. Has received daratumumab or other anti-CD38 therapies previously
  2. Is refractory to VELCADE or another PI, like ixazomib and carfilzomib (had progression of disease while receiving VELCADE therapy or within 60 days of ending VELCADE therapy or another PI therapy, like ixazomib and carfilzomib
  3. Is intolerant to VELCADE (ie, discontinued due to any adverse event while on VELCADE treatment)
  4. Has received anti-myeloma treatment within 2 weeks or 5 pharmacokinetic half-lives of the treatment, whichever is longer, before the date of randomization. The only exception is emergency use of a short course of corticosteroids (equivalent of dexamethasone 40 milligram per day [mg/day] for a maximum of 4 days) before treatment. A list of anti-myeloma treatments with the corresponding pharmacokinetic half-lives is provided in the Site Investigational Product Procedures Manual (IPPM).
  5. Has a history of malignancy (other than multiple myeloma) within 3 years before the date of randomization
  6. Has any concurrent medical condition or disease (eg, active systemic infection) that is likely to interfere with study procedures
pin location

Study Locations

Enter your ZIP code/Postal code/PIN code to locate study sites near you:

How to Apply

Contact the study center to learn if this study is a good match for you.
Email iconEmail Study Center

Study’s details


Multiple Myeloma




Phase 3

Participants needed


Est. Completion Date

Jun 2024

Treatment type



Janssen Research & Development, LLC identifier


Study number


Understanding Clinical Trials

Get answers to your questions about clinical trials.What is a clinical research?What does taking part in clinical trials involve?What should I ask the trial doctor?


Sign up to save your favorites, 
receive newsletters, resources, and alerts 
about clinical trials related to your conditions of interest.